Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study.

•We investigated a herpes zoster vaccine candidate at different antigen doses, and with or without the AS01B Adjuvant System.•All adjuvanted vaccine formulations were immunogenic and well-tolerated in adults ≥60 years of age.•Two vaccinations with the adjuvanted vaccine candidate induced a greater immune response than one.•The dose of varicella-zoster virus glycoprotein E impacted humoral but not cellular immune responses.